Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics

IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.

16 Nov 2026 · CompePharma editorial

What happened

IM Cannabis Corp. (IMCC) reported unaudited results to 30 September 2026 showing a nine-month net loss of C$13.9 million and revenue down to C$9.0 million. The asset base is smaller and the company still has a shareholders' deficit. The balance sheet was supported by fresh funding from convertible notes and a private placement. The material provided does not give the size or terms of either instrument, so the cost of that capital cannot be assessed here.

The pattern is a business whose revenue is contracting while it keeps raising external capital to stay funded. That is a different financing story from the others on the desk this week.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →